Additional file 1: of A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
- Resource Type
- Authors
- Couban, Stephen; Benevolo, Giulia; Donnellan, William; Cultrera, Jennifer; Koschmieder, Steffen; Srdan Verstovsek; Hooper, Gregory; Hertig, Christian; Maneesh Tandon; Dimier, Natalie; Malhi, Vikram; Passamonti, Francesco
- Source
- Subject
- Language
Supplementary methods. Table S1. Bone marrow fibrosis grade. Table S2. Treatment-emergent AEs of any grade that occurred in ≥ 2 patients. Table S3. AEs leading to treatment interruption or modification. Table S4. Mean (± SD) total and unbound steady-state vismodegib plasma concentration. (DOCX 24 kb)